<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>ijcicr</PublisherName> <JournalTitle>International Journal of Clinical Investigation and Case Reports</JournalTitle> <PISSN>C</PISSN> <EISSN>l</EISSN> <Volume-Issue>Volume 1, Issue 1</Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>(May-July)</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>2022</Year> <Month>07</Month> <Day>15</Day> </PubDate> <ArticleType>Surgery</ArticleType> <ArticleTitle>Krukenberg Tumor Secondary to Pancreatic Ductal Adenocarcinoma: A Case Report</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>23</FirstPage> <LastPage>28</LastPage> <AuthorList> <Author> <FirstName>Samantha</FirstName> <LastName>Sosa</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>Layla L.</FirstName> <LastName>Monroy</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Manuel</FirstName> <LastName>Lavariega</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Jose M.</FirstName> <LastName>Portela</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Rogelio A.</FirstName> <LastName>Sanchez</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Armando</FirstName> <LastName>Lopez</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Maria T.</FirstName> <LastName>Bourlon</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Sergio</FirstName> <LastName>Sanchez</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Alejandro Rossano*</FirstName> <LastName>(MEXICO)</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI>10.55828/ijcicr-11-05</DOI> <Abstract>Background: A metastatic tumor of the ovary known as Krukenburg Tumor (KT) is a mucin-rich signet-ring adenocarcinoma that arises from a gastrointestinal site in most cases and from other sites in less proportion. We describe a rare case presenting a Krukenberg tumor secondary to pancreatic ductal adenocarcinoma. Case Presentation: A 51-year-old female, who started her current condition 6 months ago, with 15 kg of weight loss, accompanied by nausea, vomiting, early satiety, and constipation. Computerized tomography showed dependent mass involving the body and tail of the pancreas with solid and cystic components, highly suggestive of a primary tumor as well as peritoneal carcinomatosis and a left ovarian mass, tumor (Krukenberg) as a first possibility. A laparoscopy was performed. The final pathology report was a pancreatic ductal adenocarcinoma with metastases to the ovary from the left salpingectomy. Conclusion: Pancreatic cancer presenting as Krukenberg tumor of the ovary is rare and easily misdiagnosed as primary ovary carcinomas, which leads to missed surgical opportunities. Resection of ovarian metastases combined with chemotherapy treatment may increase the overall survival even in patients with advanced pancreatic ductal adenocarcinoma.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>Krukenberg Tumor,Metastases,Ductal Pancreatic Adenocarcinoma ,Ovary Adenocarcinoma,Neoplasm Metástasis ,Ovarian Neoplasms</Keywords> <URLs> <Abstract>https://ijcicr.com/ubijournal-v1copy/journals/abstract.php?article_id=13986&title=Krukenberg Tumor Secondary to Pancreatic Ductal Adenocarcinoma: A Case Report</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References>Aziz M, Killeen RB, Kasi A. Krukenberg Tumor. Treasure Island (FL): StatPearls Publishing. 2022. Mendoza-Rosado F, Nunez-Isaac O, Espinosa-Marron A, Lopez-Arjona K, Davila-Martinez F. Krukenberg tumor as an incidental finding in a full-term pregnancy: a case report. J Med Case Rep. 2021;15(1):304. Meriden Z, Yemelyanova AV, Vang R, Ronnett BM. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: Analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol. 2011;35(2):276-288. Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecologic Oncology. 2014; 93(1): 87-91. Falchook GS, Wolff RA, Varadhachary GR. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol. 2008;108(3):515-519. Lyngdoh BS, Dey B, Mishra J, Marbaniang E. Krukenberg tumor. Autopsy Case Rep. 2020;10(2):e2020163. Marko J, Marko KI, Pachigolla SL, Crothers BA, Mattu R, Wolfman DJ. Mucinous neoplasms of the ovary: Radiologic-pathologic correlation. Radiographics. 2019;39(4):982-997. Kube?ek O, Laco J, and;Scaron;pa?ek J, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis. 2017;34(5):295-307. Wang SD, Zhu L, Wu HW, Dai MH, Zhao YP. Pancreatic cancer with ovarian metastases: A case report and review of the literature. World J Clin Cases. 2020;8(21):5380-5388. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: A review. JAMA. 2021;326(9):851-862. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. New Eng J Med. 2018;379(25):2395-2406.</References> </References> </Journal> </Article> </ArticleSet>